Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

121 Bio

121 Bio
Out of Business LATEST DEAL TYPE

Developer of a suite of innovative research tools designed for modification of proteins and cells and innovative cellular immunotherapies. The company's research tools will help drive fundamental new discoveries in protein structure/function and through systematic and deliberate modification of proteins, providing a platform for development of protein-based drugs with enhanced performance.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Healthcare
Primary Office
  • 700 Main Street
  • Cambridge, MA 02139
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore 121 Bio’s full profile, request a free trial.

121 Bio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-May-2017 Completed Out of Business
1. Early Stage VC (Series A) 01-Jan-2014 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

121 Bio Executive Team (4)

Name Title Board
Vanessa Winfield Operations Manager
James Gorman Ph.D Co-Founder, Chief Executive Officer, CSO and Board Member
Gregg Beloff JD Chief Financial Officer
Ramani Varanasi Chief Business Officer

121 Bio Board Members (4)

Name Representing Role Since Contact
Hidde Ploegh Ph.D Self Co-Founder & Board Member 000 0000
James Gorman Ph.D Self Co-Founder, Chief Executive Officer, CSO and Board Member 000 0000

2 Former Board Members

You’re viewing 2 of 4 board members. Get the full list »